Accès ouvert
2024
article
OpenAlex
Michael G. Ison, Alberto Papi, Eugene Athan, Robert G. Feldman et autres
BACKGROUND: The adjuvanted RSV prefusion F protein-based vaccine (RSVPreF3 OA) was efficacious against RSV-related lower respiratory tract disease (RSV-LRTD) in ≥60-years-olds over 1 RSV season. We evaluated efficacy and safety of 1 RSVPreF3 OA dose and of 2 RSVPreF3 OA doses given …
it, au, us, ca, kr, be, es, de, Afrique du Sud
(code pays fourni par la source)
Accès ouvert
2023
article
OpenAlex
Robert G. Feldman, Raffaele Antonelli Incalzi, Katie Steenackers, Dong‐Gun Lee et autres
BACKGROUND: Older adults with chronic cardiorespiratory or endocrine/metabolic conditions are at increased risk of respiratory syncytial virus (RSV)-related acute respiratory illness (RSV-ARI) and severe respiratory disease. In an ongoing, randomized, placebo-controlled, multicountry, phase 3 trial in ≥60-year-old participants, an AS01E-adjuvanted RSV prefusion …
us, it, be, kr
(code pays fourni par la source)
Accès ouvert
2023
article
OpenAlex
Alberto Papi, Michael G. Ison, Joanne M. Langley, Dong‐Gun Lee et autres
BACKGROUND: Respiratory syncytial virus (RSV) is an important cause of acute respiratory infection, lower respiratory tract disease, clinical complications, and death in older adults. There is currently no licensed vaccine against RSV infection. METHODS: -adjuvanted RSV prefusion F protein-based candidate vaccine (RSVPreF3 …
it, us, ca, kr, be, es, de, ch
(code pays fourni par la source)
Accès ouvert
2022
article
OpenAlex
Ana Florea, Lina S. Sy, Bradley K. Ackerson, Lei Qian et autres
INTRODUCTION: This observational retrospective matched cohort study evaluated the safety of a prenatal tetanus, diphtheria, acellular pertussis (Tdap) vaccination, Boostrix. We previously reported on the risk of maternal and neonatal outcomes; here we report on the risk of congenital anomalies in infants …
us, il, be
(code pays fourni par la source)
Accès ouvert
2022
article
OpenAlex
Hung Fu Tseng, Lina S. Sy, Bradley K. Ackerson, Gina S. Lee et autres
The objective of this study was to evaluate the safety of prenatal tetanus, diphtheria, acellular pertussis (Tdap) vaccination. This cohort study was conducted among pregnant members at Kaiser Permanente Southern California (KPSC). The exposed cohort consisted of women who received Tdap vaccine …
us, be
(code pays fourni par la source)
Accès ouvert
2022
article
OpenAlex
Anastasia Kuznetsova, Maria Angeles Ceregido, Anne Jourquin, Laura Cámpora et autres
BACKGROUND: GSK initiated a Pregnancy Registry in the United States (US) for the reduced-antigen-content tetanus-diphtheria-acellular pertussis (Tdap; Boostrix, GSK) vaccine with the aim to detect and describe pregnancy outcomes in women vaccinated with Boostrix 28 days before estimated conception or during pregnancy. …
be
(code pays fourni par la source)
Accès ouvert
2020
article
OpenAlex
Asmik Asatryan, Nadia Meyer, Michael Scherbakov, Victor Romanenko et autres
As vaccine-induced immunity and protection following natural pertussis infection wane over time, adults and adolescents may develop pertussis and become transmitters to unprotected infants. In Russia, diphtheria and tetanus but not pertussis-containing vaccines are registered for older children, adolescents, or adults. The …
be, ru
(code pays fourni par la source)
Accès ouvert
2019
article
OpenAlex
Ana Strezova, Himal Lal, Igwebuike Enweonye, Laura Cámpora et autres
BACKGROUND: This study evaluated immunogenicity and safety of the adjuvanted recombinant zoster vaccine (RZV) and the reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine (Tdap) when co-administered in adults aged ≥50 years. METHODS: In this open label, multi-center study (NCT02052596), participants were randomized 1:1 to the …
be, us, nl
(code pays fourni par la source)
Accès ouvert
2019
article
OpenAlex
Alemnew F. Dagnew, Osman İlhan, Won Sik Lee, Dariusz Woszczyk et autres
us, tr, kr, pl, gb, es, tw, pa, be, au, ca, de
(code pays fourni par la source)
Accès ouvert
2019
article
OpenAlex
Adriana Bastidas, Javier de la Serna, Mohamed El Idrissi, Lidia Oostvogels et autres
Importance: Herpes zoster, a frequent complication following autologous hematopoietic stem cell transplantation (HSCT), is associated with significant morbidity. A nonlive adjuvanted recombinant zoster vaccine has been developed to prevent posttransplantation zoster. Objective: To assess the efficacy and adverse event profile of the …
be, es, de, fr, tr, cz, il, us, it, kr, gb, my, au
(code pays fourni par la source)
Accès ouvert
2019
article
OpenAlex
Marta López‐Fauqued, Laura Cámpora, Frédérique Delannois, Mohamed El Idrissi et autres
BACKGROUND: The ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229) phase 3 clinical trials showed that the adjuvanted recombinant zoster vaccine (RZV) was ≥90% efficacious in preventing herpes zoster in adults. Here we present a comprehensive overview of the safety data from these studies. METHODS: …
be, ch, au, es, us, ca, fi, br, mx, se, cz, de, it, jp, tw, Sénégal, rs
(code pays fourni par la source)
Accès ouvert
2019
article
OpenAlex
Peter Vink, Josep Ramón, Ana Sánchez‐Fructuoso, Sung-Joo Kim et autres
BACKGROUND: The incidence of herpes zoster is up to 9 times higher in immunosuppressed solid organ transplant recipients than in the general population. We investigated the immunogenicity and safety of an adjuvanted recombinant zoster vaccine (RZV) in renal transplant (RT) recipients ≥18 …
us, es, gb, kr, ca, fi, pa, tw, be, nl, it, ch, de
(code pays fourni par la source)